This study is being conducted to evaluate the long-term safety of apremilast in children and young people. The research focuses on individuals living with Behçet’s disease, a long-term condition that causes inflammation throughout the body, or Juvenile Psoriatic Arthritis, a type of chronic joint inflammation that begins in childhood. In both conditions, the study specifically looks at those experiencing oral ulcers, which are painful sores located inside the mouth.

Participants in this study will take apremilast as an oral medication, which can be provided in the form of a film coated tablet or an oral solution. This is an open-label study, meaning that both the researchers and the participants will know which medication is being used. The study is a long-term extension, meaning it follows individuals who have previously participated in other research studies involving this same medication.